12:00 AM
 | 
Aug 10, 2015
 |  BC Week In Review  |  Company News  |  Deals

Epirus, Polpharma deal

Epirus partnered with Polpharma to develop and commercialize biosimilars BOW015, BOW050 and BOW070. BOW015 is a biosimilar of Remicade infliximab from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) and Merck & Co....

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >